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E-mail address: kiyama.r@aist.go.jp (R. Kiyama).To compare gene expression proﬁles in response to estrogen or 17b-estradiol (E2) and a mycotoxin,
zearalenone (ZEA), and its analogues (collectively termed ZEA compounds), breast cancer MCF-7
cells were treated with 10 nM of E2 or ZEA compounds including ZEA, a-zearalenol, b-zearalenol,
zearalanone, a-zearalanol and b-zearalanol. Expression proﬁles for 120 estrogen-responsive genes
were subjected to cluster and statistical analyses using correlation coefﬁcients or R-values. We
found that all of the ZEA compounds stimulated the growth of MCF-7 cells, as much as E2, and
showed similar expression proﬁles to that of E2 (R-values ranged from 0.82 to 0.96). The effect of
ZEA compounds was likely mediated by estrogen-receptor-dependent Erk1/2-signaling. These
results provide clues to understand the mechanism of their estrogen-like action.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Zearalenone (ZEA), also known as F-2 toxin, is a non-steroidal
estrogenic mycotoxin produced by various species of Fusarium
[1,2]. ZEA and its analogues constitute an important class of endo-
crine disruptors, which have estrogenic effects and inﬂuence
reproduction, such as 17b-estradiol (E2) [3]. In fact, ZEA and its
metabolites were found to bind to estrogen receptors [4,5]. Several
lines of evidence show that ZEA is associated with hyperestroge-
nism and physiological alterations of the reproductive tract [6], af-
fects conception, implantation and fetal development [7], and also
disturbs the ovulation cycle and reduces the body sizes of domestic
animals, particularly swine [8] and rats [9].
Toxic effects of ZEA were demonstrated at the cellular and
molecular levels, such as the induction of apoptosis, DNA fragmen-
tation [10], production of micronuclei [11], chromosomal aberra-
tions [12], and formation of DNA adducts [13]. All these toxic
effects are unlikely to be due only to the estrogenic activity of
ZEA, and other toxic effects, not related to the afﬁnity for estrogen
receptors, could be involved. Several processes are known to play
roles in the molecular events leading to cell damage, particularlychemical Societies. Published by E
; ZAL, zearalanone; DCC-FBS,
SRB, sulforhodamine Binhibition of the synthesis of cellular macromolecules and induc-
tion of lipid peroxidation. Lipid peroxidation is one of the cellular
pathways involved in oxidative damage and underlies ZEA-induced
apoptosis [14].
Anti-apoptotic effects of ZEA at low concentrations were re-
ported. The inhibition of apoptosis by ZEA was correlated with al-
tered expression levels of the apoptosis-related modulators bax
and bcl-2. Thus, the anti-apoptotic action of ZEA in MCF-7 cells
was closely linked with the down-regulation of bax expression,
which is different from its behavior in the anti-apoptotic effect of
E2, and up-regulation of bcl-2 expression [15]. Therefore, the estro-
genic activity of ZEA and the signaling pathway involved is not
completely the same as that of E2, and there may be speciﬁc types
of modulation of the estrogenic signal for each of ZEA compounds.
To analyze the differences in the effect of estrogenic chemicals on
gene expression, human breast cancer cells or mouse uterus were
treated with E2, phytoestrogens or xenoestrgens, and global gene
expression proﬁles were analyzed by using DNA microarrays
[16–18]. The expression proﬁles may depend on the subtypes of
estrogen receptors [18].
In this study, we tried to evaluate the estrogenecity of ZEA and
its analogues at the molecular level by using a focused microarray.
DNA microarrays have opened a new paradigm in toxicology [19],
by characterizing the genome-wide response of gene expression
stimulated by endocrine-disrupting chemicals and by offering a
means of understanding the biological effects and mechanisms oflsevier B.V. All rights reserved.
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this technology to several chemicals of artiﬁcial and natural origins
[20–24]. Here, we obtained expression proﬁles of estrogen-respon-
sive genes for ZEA and its analogues and attempted to identify spe-
ciﬁc genes or biological pathways to understand their mode of
action.2. Materials and methods
2.1. Chemicals, cell culture and RNA isolation
Natural estrogen E2, and ZEA and its derivatives were purchased
fromWako Pure Chemical Industries (Osaka, Japan) and Sigma–Al-
drich (St. Louis, MO), respectively. All the test compounds were dis-
solved in dimethylsulfoxide with the ﬁnal concentration of the
solvent not more than 0.1% of the culture medium. MCF-7 cells
were obtained from the Japanese Collection of Research Biosources
Cell Bank (National Institute of Health Science, Tokyo, Japan). Cells
were maintained in phenol red-free RPMI 1640 medium (Invitro-
gen) containing 10% dextran-coated charcoal-treated fetal bovine
serum (DCC-FBS) and incubated at 37 C in an atmosphere of 5%
CO2–95% air for 3 days. E2 and ZEA compounds were added individ-
ually to the medium and the ﬁnal concentration for each was
10 nM. After incubation, total RNAwas isolated using Isogen (Wako
Pure Chemical Industries) according to the manufacturer’s instruc-
tions and quantiﬁed by measuring optical density at 260 nm.
2.2. Sulforhodamine B assay
The Sulforhodamine B (SRB) assay for measuring cell prolifera-
tion was performed according to Skehan et al. [25] with somemod-
iﬁcations as follows. Cells (104 cells/ml) were seeded on 24-well
plates with DCC-FBS medium for 3 days at 37 C. The cultures were
then incubated in the presence of 10 nM E2 or ZEA (0.01 nM,
0.1 nM, 1 nM, 10 nM, 100 nM, 1 lM, or 10 lM) for 3 more days.
Next, the cells were ﬁxed in 10% cold trichloroacetic acid at 4 C
for 30 min, stained with 200 ll of 0.4% SRB, and dissolved in 1%
acetic acid for 20 min. A 200-ll volume of 10 nM unbuffered tris-
base was used for the solubilization of bound protein. Solutions
were transferred into 96-well plates to measure optical density
at 490 nm. The background level was subtracted by measuring
optical density at 650 nm.
2.3. cDNA microarray and data analysis
A customized cDNA microarray (EstrArray; InfoGenes, Tsukuba,
Japan) was used as described [20]. It was manufactured by
mechanical spotting of cDNA (approximately 0.5–1.5 kb) on glass
slides containing 172 estrogen-responsive genes (108 up-regulated
and 64 down-regulated genes). In addition, it contains extra 31
expression/calibration markers. However, for the present study,
we have chosen 120 estrogen-responsive genes with greater statis-
tical stability, from among the original 172 genes [22]. The EstrAr-
ray assay was performed in triplicate using independently
prepared sets of total RNA. Labeling of cDNA probes, hybridization
on EstrArray, signal detection and data analyses were done as de-
scribed previously [22]. The ratios of Cy3- and Cy5-signal intensi-
ties (Cy3/Cy5) were calculated and log2-transformed. Then, log2
(Cy3/Cy5) values were normalized against an average of 28 inter-
nal control genes. Thus obtained log2 (Cy3/Cy5) values from two
spots on the microarray were averaged and used for further anal-
yses. Average-linkage hierarchical clustering was performed using
the Cluster program [26] and the results were displayed with the
Tree View program [26]. Coefﬁcients of correlations between gene
expression proﬁles and p-values were calculated using SPSS 12.0J(SPSS Japan; Tokyo, Japan). The DNA microarray data discussed
here have been deposited in NCBI’s Gene Expression Omnibus
[27] and are accessible through the Accession Number GSE15249
(http://www.ncbi.nlm.nih.gov/geo/).
The UniGene names of the 120 genes analyzed are based on the
Entrez Gene database (www.ncbi.nlm.nih.gov). The categories and
gene functions for classiﬁcation were based on the Gene Ontology
terms in the Entrez Gene database. If there were several functions,
only one was used as representative for each gene.
2.4. Real-time quantitative reverse transcription-PCR
Total RNA was extracted from MCF-7 cells as described
previously [20]. First strand cDNA was synthesized from 1 lg of
total RNA using a SuperScript III Platinum Two-Step qRT-PCR kit
(Invitrogen). Quantitative real-time PCR was performed with a
LightCycler (Roche; Basel, Switzerland) using Platinum SYBR-
Green (Invitrogen) for detection. The denaturing of cDNA at 95 C
for 2 min was followed by 45 cycles of denaturation at 95 C for
5 s, annealing at 60 C for 5 s and extension at 72 C for 20 s.
b-Actin was used as a control. The primer sequences are:
TFF1, 50-TTGTGGTTTTCCTGGTGTCA-30 and 50-CCGAGCTCTGGGAC-
TAATCA-30; SH3BP5, 50-AAAGAACCAGAGCTGGGAAGATG-30 and
50-ATCGTGGGATAAAGTGGAGAGGA-30; AGTR1, 50-CCTGGCTA-
TTGTTCACCCAAT-30 and 50-GGGACTCATAATGGAAAGCACA-30;
ARGHDIA, 50-CCTCACTAGCCTCTACTCCCTGT-30 and 50-ACTGAG-
GTGACTTGAGTGTTGG-30 actin, 50-CTGGAACGGTGAAGGTGACA-30
and 50-AAGGGACTTCCTGTAACAATGCA-30. The data were normal-
ized as a ratio to the control and expressed as the log2-transformed
fold-change in mRNA relative to that before chemical treatment.
2.5. Western blotting
The protein was electro-transferred onto nitrocellulose mem-
branes (Millipore; Billerica, MA) using a semi-dry transfer cell
(BIO-RAD; Hercules, CA) at 1 mA/cm2 for 2 h. The membranes were
soaked in Tris-buffered saline containing 0.1% Tween 20 and 5%
BSA (TBST-BSA), and then probed overnight at 4 C with a phos-
pho-Erk1/2 antibody (Cell Signaling Technologies; used after a
1:1000 dilution in TBST-BSA), which detects phosphorylated forms
of Erk1/2. After being washed with TBST, the membranes were
incubated in TBST-BSA containing a horseradish peroxidase-conju-
gated goat antibody against rabbit IgG (Cell Signaling Technolo-
gies) for 1 h and then visualized with the ECL-plus Western
Blotting Detection System (Amersham Pharmacia Biotech, Arling-
ton Heights, IL) using Cool Saver AE-6955 (ATTO; Tokyo, Japan).
After stripping, the same blot was re-probed with an anti-total
Erk1/2 antibody (Cell Signaling Technologies) to the relative level
of total Erk1/2 protein. The intensity of the bands was quantiﬁed
by the Multi Gauge Ver 3.0 software (FUJIFILM). For statistical eval-
uation of the data, p-values were calculated using SPSS 12.0J.3. Results
3.1. Cell proliferation assay with ZEA compounds
First, we examined the effects of ZEA compounds on cell prolifer-
ation. We used the SRB assay to examine the proliferation of MCF-7
cells treated with either ZEA, a-ZEA, b-ZEA, ZAL, a-ZAL, or b-ZAL, or
with natural estrogen (E2) as a control (Fig. 1A). All the ZEA com-
pounds induced cell proliferation at relatively low concentrations,
comparable to that of E2 (Fig. 1B–G), conﬁrming their estrogenicity
as reported [4,5]. Furthermore, all excepta-ZEA suppressed cell pro-
liferation at 10 lM. On the other hand, a-ZEA induced cell prolifer-
ation over a broad range of concentrations, from 0.01 nM to 10 lM.
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Fig. 1. Chemical structure and effects on cell proliferation of E2 and ZEA compounds. (A) Chemical structure of E2 and ZEA compounds. (B–G) Cell proliferation assay for ZEA
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ZEA compounds in the DNA microarray assay (Fig. 2).
3.2. Expression proﬁles for ZEA compounds in MCF-7 cells
We then examined expression proﬁles of estrogen-responsive
genes using a customized DNA microarray (Fig. 2). A set of 120highly reproducible estrogen-responsive genes [22] was used for
the assay and the data were subjected to a correlation analysis
based on linear regression, with correlation coefﬁcients or R-values
used to compare gene expression proﬁles (Fig. 2). First, the proﬁles
for these ZEA compounds were compared with that of E2 (Fig. 2). R-
values ranged from 0.93 to 0.96 for ZEA compounds, except for b-
ZEA, which showed an R-value of 0.82 (Fig. 2A–F). On the other
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Fig. 2. Correlation of gene expression proﬁles between respective pairs of E2 and ZEA compounds. Expression proﬁles of 120 estrogen-responsive genes were compared
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2380 M. Parveen et al. / FEBS Letters 583 (2009) 2377–2384hand, a wide range of R-values (0.66 to 0.95) were found for the
expression proﬁles between pairs of ZEA compounds. The pair a-
ZAL and b-ZAL showed the highest R-value (0.95) (Fig. 2U) and
the pair b-ZEA and b-ZAL the lowest (0.66) (Fig. 2P), which suggests
that some genes are regulated in different ways in response to dif-
ferent ZEA compounds. The expression proﬁles were also subjected
to a cluster analysis (Fig. 3A). The results indicate that E2 and all
the ZEA compounds examined here had very similar expression
proﬁles and E2 was closer to ZAL, a-ZEA and ZEA than the others.3.3. Different effects on signaling-related genes by ZEA compounds
The genes used in our microarray assay can be categorized into
six broad groups (enzymes, signaling, proliferation, transcription,
transport and others) based on their known functions ([22]; see
Fig. 3A). To understand functional differences among the genes in
response to different ZEA compounds, we analyzed gene expres-
sion proﬁles by comparing R-values for each functional group.
We ﬁrst compared the expression proﬁles for E2 with those for
ULK1
PVR
TFF1
SH3BP5
PGR
PIK3C3
EDN2
ESR1
ILK
CTNND2
PRKCSH
PRKCD
AGTR1
RHOC
LGALS3BP
PTPN18
ARNT2
IGFBP5
ARHGDIA
PCSK6
NPY1R
IGFBP5
β-
ZE
A
ZE
A
α
-
ZE
A
β-
ZA
L
α
-
Z A
L
No data
8
6
4
2
1/2
1
1/4
1/6
1/8
Enzymes
Signaling
Proliferation
Transcription
Transport
Others
ZA
L
E2
PSAT1
ASNS
PCK2
WARS
MTHFD2
PHGDH
ASS
GOT1
GFPT1
SHMT2
SERPINA3
CTSD
SCD
CPT1A
ACO2
SFTPB
DHCR24
PMPCA
CDIPT
SORD
FUT8
ENO3
ENO2
FBP1
ULK1
TFF1
NPY1R
SH3BP5
PGR
EDN2
PIK3C3
ESR1
LLK
PRKCSH
CTNND2
PRKCD
AGTR1
PTPN18
LGALS3BP
RHOC
ARNT2
ARHGDIA
IGFBP5
PCSK6
IGFBP5
PVR
AREG
PDZK1
AREG
MGP
IFRD1
ISG20
IGFBP4
FTH1
LAMP3
TSPAN1
PMP22
TP53I11
TACSTD2
QSCN6
CAPNS1
CEBPB
TCEA1
TCEA1
TAF9
ATF3
NRIP1
FOS
GTF2I
ENO1
Clorf19
SLC1A4
SLC1A5
RCN1
XPOT
TCN1
LCN2
CLIC4
IMP4
U5-116KD
EIF3S9
CDH18
SLC12A2
EFEMP1
PMAIP1
TPD52L1
HSPA5
PEG10
SH3BGR
SH3BGR
H3F3B
TRA1
LOC401397
AIM1
CBX1
TM4SF1
SYNGR2
HSPA1A
β-
ZE
A
β-
ZA
L
α
-
ZA
L
ZE
A
α
-
Z E
A
ZA
L
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shown). The results indicate that E2 and ZEA compounds are quite
similar. R-values of all functional groups except the signaling-re-
lated genes were again very similar among the ZEA compounds.
The signaling-related genes examined here totaled 20 and their
expression proﬁles as a whole clearly showed differences among
three groups in the cluster analysis (Fig. 3B); the group of b-ZEA,
the group of a-ZAL and b-ZAL, and the rest. Obviously, these rela-
tionships could be caused by differences in the response of certain
genes. The signaling-related genes used here can be further classi-
ﬁed according to signaling pathways, such as mitogen-activated
protein kinase- (MAPK-) related genes (SH3BP5 for example),
Akt2-related genes (PRKCD for example) and Ras superfamily genes
(RHOC and ARHGDIA for example). We examined the expressionlevels of some signaling-related genes by real-time RT-PCR
(Fig. 4). The results of four genes showing up-regulation (TFF1
and SH3BP5; Fig. 4E and F) or down-regulation (AGTR1, and ARHG-
DIA; Fig. 4G and H) clearly validated the results of the microarray
assay (Fig. 4A–D).
3.4. Activation of Erk1/2 in MCF-7 cells by treatment with ZEA
compounds
External growth factors can activate the rapid signaling path-
way within an hour, eventually inducing cell proliferation [28].
Here, we examined whether ZEA compounds can activate the
extracellular-signal-regulated kinase 1/2 (Erk1/2) to induce cell
proliferation. The levels of the phosphorylated forms and total
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10 nM of ZEA compounds and the results compared with those
for E2 at the same concentration (Fig. 5). Phosphorylation of
Erk1/2 was clearly observed in response to all ZEA compounds
examined (Fig. 5A). To further substantiate this observation, we
pretreated the cells with ICI 182 780 and examined whether it
blocks the phosphorylation. Consistent with a previous study
[23], phosphorylation of Erk1/2 was inhibited in E2-treated cells
by the pretreatment with ICI 182 780 (Fig. 5B and C). Also, the pre-
treatment with ICI 182 780 resulted in the inhibition of phospho-
Erk1/2 (P-Erk) in the cells treated with ZEA compounds. This obser-
vation clearly suggests that the signaling pathway was very similar
between E2 and the ZEA compounds.
4. Discussion
4.1. Estrogenic activity of ZEA compounds
It is believed that ZEA compounds can attain an E2-like confor-
mation very easily. This structural ﬂexibility enables them to bind
ER as strongly as natural estrogen [29]. Consistent with this, we ob-
served that ZEA compounds induced strong estrogenic signals at
very low concentrations, as low as 0.01 nM. This observation is
quite consistent with a previous study in which various ZEA com-
pounds were found to stimulate the proliferation of MCF-7 cells at
the equivalent concentrations [30]. On the basis of EC50 values, ZEA
compounds were ranked as follows: a-ZEA = a-ZAL = b-ZAL =
ZEA > b-ZEA [30]. Similarly, we also observed strong estrogenic
activity for a-ZEA and a-ZAL and weak activity for b-ZEA (Fig. 1C,F and D) and could be ranked as follows: a-ZEA = a-ZAL > ZAL >
ZEA = b-ZAL > b-ZEA. Consistent with this observation, when gene
expression proﬁles were compared, all of the ZEA compounds
except b-ZEA showed high correlation coefﬁcients with E2. The
cluster analysis of gene expression proﬁles also categorized
b-ZEA further away from E2 than other compounds. Collectively,
it might suggest that a-ZEA could be structurally closer to natural
estrogen than b-ZEA.
4.2. Different effects on genes by ZEA compounds
Among the functional groups of the genes examined here, the
genes related to signaling contributed to signiﬁcant differences in
the expression proﬁles among three subgroups of ZEA compounds;
b-ZEA alone, a-ZAL and b-ZAL, and ZEA, a-ZEA and ZAL (Fig. 3B).
We further examined the genes contributing to this difference by
ANOVA and t-test but could not ﬁnd genes independently showing
differences at signiﬁcant levels (p < 0.05) except PVR and IGFBP5
(data not shown). A part of the reason for this is that the degree
of expressional difference for these genes is not very high, although
sets of genes, probably grouped by more speciﬁc functions, could
collectively show more signiﬁcant differences. Furthermore, the
functions of many of the signaling-related genes remain unclear.
PVR has been recognized as a poliovirus receptor but its intracellu-
lar signaling is not known. Down-regulation of IGFBP5, a growth
inhibitor and pro-apoptotic agent in breast cancer cells [31], would
result in activation of cell proliferation as observed here, although
the mechanism is not well studied. On the other hand, there are
several classes of genes; Ras-related genes, ULK1, RHOC and ARHG-
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Fig. 5. Activation of Erk1/2 by ZEA compounds. (A) Time course of phosphorylation. Cells were treated with ZEA compounds for the periods as indicated. (B) Inhibition of the
phosphorylation of Erk1/2 with ICI 182 780. Cells were treated with 1 lM ICI 182 780 (ICI) for 60 min prior to their incubation with E2 or ZEA compounds for 5 min. The level
of P-Erk was examined by Western blot analysis. Cells were lysed in SDS sample buffer and protein samples were electrophoresed in SDS–15% polyacrylamide gels,
transferred to nitrocellulose membranes and probed with an antibody speciﬁc to phospho-Erk1/2 (P-Erk). The level of protein loading was conﬁrmed with an antibody that
recognizes total Erk1/2 (T-Erk) protein. (C) Quantitative analysis of Western blot data for the inhibition of the phosphorylation of Erk1/2 with ICI 182 780. The intensity of the
band for each chemical was normalized with that of the control (DMSO), and the average and S.D. of the ratios (ICI +/) for each chemical after repeating the assay three times
(including the data shown in panel B) are shown. Statistical signiﬁcance of the deviation of the response to each chemical from no change (i.e. ICI +/ = 1.0) was analyzed by t-
test. *p < 0.05.
M. Parveen et al. / FEBS Letters 583 (2009) 2377–2384 2383DIA; receptors and their ligands, NPY1R, PGR, AGTR1, ARNT2 and
PVR; kinases/phosphatases and their binding proteins, ULK1,
SH3BP5, PI3K3C3, ILK, PRKCSH, PRKCD and PTPN18. These genes
could activate speciﬁc Ras proteins and other signaling proteins
thereby contributing to cell growth and proliferation. Down-regu-
lation of apoptosis-related genes, PRKCD and IGFBP5, would be a
part of this.
4.3. ZEA compounds and signaling
Previous studies showed that the pathway including Erk1/2
phosphorylation mediates the estrogen-like signal for cell prolifer-ation induced by ginsenoside Rg1, genistein or equol in MCF-7 cells
[32,33]. The inhibition of Erk1/2 phosphorylation was shown to
cause the reduced expression of estrogen-responsive genes, such
as pS2 [32]. In this study, we found that ZEA compounds can trigger
a rapid activation of the Erk1/2 pathway within 5 min. The pattern
of signal activation of MCF-7 cells with ZEA compounds is similar
to that in response to E2. However, the underlying mechanism of
E2-mediated activation of Erk1/2 is not well understood. Reports
in the last decade proposed two models to explain E2-mediated
non-genomic rapid cell proliferation. One model suggests that
membrane-bound classic ER a/b together with other factors
mediates the E2-induced signaling [34,35]. Meanwhile, the other
2384 M. Parveen et al. / FEBS Letters 583 (2009) 2377–2384model indicates the involvement of another membrane-bound G-
protein-coupled protein, GPR30, in E2-mediated estrogenicity
[36,37]. The inhibition of Erk1/2 phosphorylation with ICI
182 780 in the cells treated with ZEA compounds (Fig. 5) indicates
that membrane-bound ER a/b could be associated with the estro-
genic action mediated by ZEA compounds. On the other hand, a de-
layed activation of Erk1/2 is involved in cell proliferation induced
by genistein or equol in an ICI 182 780-independent manner
[32]. Therefore, Erk1/2 phosphorylation should be involved in dif-
ferent receptors and their downstream signaling pathways with
proper timing and partners for its actions.
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